Navigation Links
Two Antidepressants Given to Dementia Patients Ineffective: Study
Date:7/19/2011

By Alan Mozes
HealthDay Reporter

TUESDAY, July 19 (HealthDay News) -- The antidepressants most often prescribed to treat depression in dementia patients provide no appreciable relief, and may raise the risk for serious side effects, new British research suggests.

"The two classes of antidepressants most likely to be prescribed for depression in Alzheimer's disease are no more effective than placebo," the study authors said.

The drugs in question are Zoloft (sertraline), and Remeron (mirtazapine).

"In our study, there were more adverse reactions in individuals treated with antidepressants than there were with placebo," the research team added. "Clinicians and investigators need to reframe the way they think about the treatment of people with Alzheimer's disease who are depressed, and reconsider routine prescription of antidepressants."

Led by Sube Banerjee of the Institute of Psychiatry at Kings College London in England, the authors reported their findings online July 19 in The Lancet.

Banerjee and his colleagues focused on 325 patients being treated at any of nine health centers across England for probable or possible Alzheimer's disease. The patients were also subject to bouts of depression lasting at least a month, and all registered above a minimum threshold during dementia-related depression exams.

None had been prescribed antidepressants prior to the study launch, nor were any in a critical stage of depression involving suicidal thoughts.

The patients were divided into three 13-week treatment groups. One group received 150 milligrams (mg) a day of sertraline; a second group received 45 mg a day of mirtazapine; and a third took sugar pills (placebos).

After three months, the authors found no difference in the incidence of depression among the three groups. The lack of an apparent benefit attributable to either sertraline or mirtazapine continued almost 10 months after the study's start, according to a journal news release.

Also, while about a quarter of those given placebos experienced adverse reactions as a result of treatment, that figure rose to between 41 percent and 43 percent in the groups given an antidepressant. Such side effects were also more likely to be serious among the antidepressant recipients than among the placebo group.

Dr. Henry Brodaty, an aging and dementia specialist at the University of New South Wales in Sydney, Australia, and author of an accompanying journal editorial, said the trial "has underscored the need for clinicians to think about creative alternatives to drug treatment for management of depression in people with dementia." It is important to use evidence-based techniques and to work in partnership with family caregivers, he wrote in the news release.

More information

For more on dementia and depression, visit the Alzheimer's Society.

--Alan Mozes

SOURCE: July 19, 2011, The Lancet, news release


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Research reveals that 10 percent of middle-aged Europeans are on antidepressants
2. Common Painkillers May Blunt Antidepressants
3. Antidepressants may not improve all symptoms of depression, UT Southwestern researchers find
4. U. Iowa study suggests antidepressants aid physical recovery in stroke
5. Study Hints at Link Between Antidepressants and Heart Trouble
6. Antidepressants linked to thicker arteries
7. Decrease in suicide not linked to newer antidepressants
8. Autism: Lack of evidence for antidepressants
9. Certain Popular Antidepressants Linked to Cataracts in Seniors
10. Antidepressants in pregnancy increase risk of miscarriage
11. Antidepressants May Improve Heart Health
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Two Antidepressants Given to Dementia Patients Ineffective: Study  
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: